Drug Trial Radar · NCT01124565
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
Last checked: Nov 19, 2026Latest source record: Jan 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
May 2010
Primary completion
Jul 2010
Study completion Jul 2010
Sponsor
- Lead sponsor
- Revance Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 17, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.
Conditions
- Lateral Canthal Lines
- Crow's Feet
- Facial Wrinkles
Interventions
RT001Drug
RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of treatment-emergent adverse events based on safety assessments.Time frame: 4 weeks and 8 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Total Skin & Beauty Dermatology Center, PC
Birmingham, Alabama
Therapeutics Clinical Research
San Diego, California
Skin Specialists, PC
Omaha, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.